TL1A Inhibitors for Crohn's Disease: A New Drug Class

For many of us living with Crohn's disease, existing treatments can control inflammation but do little to address the intestinal scarring that leads to strictures, hospitalizations, and surgery. That is why a new class of biologic drugs - TL1A inhibitors for Crohn's disease - has captured attention across the gastroenterology world. These investigational therapies target a pathway involved in both inflammation and fibrosis, a dual mechanism no currently approved treatment offers. With Phase 2 trial results already in hand and Phase 3 studies underway, here is what patients need to know.

Key Takeaways

• In the RELIEVE UCCD Phase 2b trial, 48% of Crohn's patients on duvakitug 900mg achieved endoscopic response at week 14, versus 13% on placebo - a 35-percentage-point difference (1)
• Tulisokibart achieved endoscopic response in 26% of patients at week 12 in the APOLLO-CD Phase 2a trial, compared with a 12% historical placebo rate (2)
• TL1A inhibitors may be the first drug class to target both gut inflammation and intestinal fibrosis, the scarring process that causes strictures in up to 50% of Crohn's patients within a decade
• Preclinical studies showed TL1A inhibition reversed collagen buildup in gut tissue back to pre-inflamed levels (3)
• Companion diagnostics using genetic biomarkers could help identify which patients are most likely to respond, bringing personalized medicine closer to reality

What Is TL1A and Why Does It Matter?

TL1A (Tumor Necrosis Factor-like cytokine 1A) is a protein in the immune system that has emerged as a key driver of both chronic inflammation and tissue scarring in Crohn's disease. Understanding this pathway helps explain why blocking it could offer something genuinely different from the biologics many of us already use.

The TL1A/DR3 Pathway Explained

TL1A works by binding to a receptor called death receptor 3 (DR3) on the surface of immune cells and other cell types in the gut. When TL1A locks onto DR3, it triggers two harmful processes simultaneously: it activates immune T-cells that drive inflammation, and it directly stimulates fibroblasts - the cells responsible for producing collagen and creating scar tissue in the intestinal wall (4).

Think of TL1A as a signal that not only calls immune cells to attack the gut lining but also tells repair cells to overproduce collagen, gradually thickening and narrowing the intestinal passage. This dual role is what makes TL1A such an appealing drug target.

How TL1A Differs from Existing Biologics

If you are familiar with anti-TNF therapies like infliximab or adalimumab, or with newer IL-23 inhibitors, you know these drugs primarily target inflammatory pathways. They can be remarkably effective at calming inflammation, but they do not directly address the fibrotic process that causes strictures.

TL1A inhibitors occupy a unique position in the biologic treatment landscape. By blocking TL1A, these drugs may tackle both sides of the disease simultaneously - quieting the immune attack on the gut and reducing the abnormal scarring response. First-in-human treatment data showed that anti-TL1A therapy reduced expression of genes associated with extracellular matrix remodeling and fibrosis (3), offering early evidence that this dual mechanism works in real patients.

The Dual Promise: Treating Inflammation and Fibrosis

The potential to address fibrosis alongside inflammation is what truly sets TL1A inhibitors apart. For patients who have experienced stricturing disease, this is not an abstract scientific distinction - it could change the trajectory of the condition.

Why Fibrosis Matters for Crohn's Patients

Intestinal fibrosis is one of the most challenging complications of Crohn's disease. Up to 50% of patients develop strictures - narrowings caused by scar tissue buildup - within 10 years of diagnosis. These strictures can cause bowel obstructions, severe pain, and often require surgical resection. The frustrating reality is that even when inflammation is well controlled with current therapies, fibrosis can continue to progress.

No currently approved Crohn's treatment directly targets intestinal fibrosis, making TL1A inhibitors potentially the first drug class designed to address this unmet need. For the many patients who live with the constant concern that strictures may be developing silently, this represents a meaningful shift in what treatment might achieve.

Preclinical Evidence for Anti-Fibrotic Effects

The laboratory data supporting TL1A's role in fibrosis is compelling. Preclinical research demonstrated that TL1A inhibition reversed collagen deposition in the gut mucosa back to pre-inflamed levels (3). In other words, blocking TL1A did not merely slow scarring - it appeared to undo some of the damage that had already occurred.

Additionally, first-in-human anti-TL1A treatment data showed reduced expression of genes associated with extracellular matrix remodeling and fibrosis (3). While these early findings need confirmation in larger trials, they suggest that the anti-fibrotic potential observed in the lab is translating into measurable biological effects in patients.

Clinical Trial Results So Far

Two TL1A inhibitors have progressed furthest in clinical trials for Crohn's disease, and both have produced encouraging results. These are still early-stage findings, but they give us a meaningful window into what this drug class may offer.

Tulisokibart (Merck): APOLLO-CD Phase 2a

Tulisokibart, developed by Merck (known as MSD outside the United States), was studied in the APOLLO-CD Phase 2a induction trial. This study found that tulisokibart achieved endoscopic response in 26% of Crohn's patients at week 12, significantly higher than the 12% historical placebo rate (2). The drug showed an acceptable safety profile with mostly mild-to-moderate adverse events.

While a 26% endoscopic response rate may sound modest, it is important to put this in context. This was a Phase 2a study - an early trial designed primarily to confirm that the drug is working and to identify the right dose. Phase 2a studies typically enroll smaller patient populations, and the results serve as a foundation for the larger, more definitive Phase 3 trials now underway.

Duvakitug (Teva/Sanofi): RELIEVE UCCD Phase 2b

Duvakitug, co-developed by Teva and Sanofi, delivered particularly striking results in the RELIEVE UCCD Phase 2b trial. At the higher 900mg dose, duvakitug achieved endoscopic response in 48% of patients at week 14, compared to just 13% on placebo - a placebo-adjusted difference of 35 percentage points (1).

These numbers are notable. A 35-percentage-point advantage over placebo is a substantial treatment effect, especially in a disease as complex as Crohn's. The trial also showed dose-dependent improvements, with higher doses producing better outcomes, which strengthens confidence that the drug is genuinely working through its intended mechanism.

Both tulisokibart and duvakitug showed acceptable safety profiles in their respective trials, with most adverse events being mild to moderate in severity. However, these are induction (short-term) trial results, and longer studies are essential to understand durability of response and long-term safety.

Other TL1A Inhibitors in the Pipeline

Tulisokibart and duvakitug are not the only TL1A inhibitors in development. Several other pharmaceutical companies are investing in this drug class, which signals strong industry confidence in the approach.

Xencor's XmAb942 is an extended half-life anti-TL1A antibody entering Phase 2b studies. The extended half-life design could mean less frequent dosing for patients - an important practical consideration for anyone managing a chronic condition. Vial is also developing a novel subcutaneous anti-TL1A antibody currently in Phase 1 trials.

The breadth of investment across multiple companies is encouraging. When several independent pharmaceutical organizations pursue the same target, it generally reflects robust preclinical evidence and a shared scientific conviction that the pathway is worth targeting. For patients, this competition may ultimately mean more treatment options and potentially faster development timelines.

Companion Diagnostics and Personalized Medicine

One of the most exciting aspects of TL1A inhibitor development is the parallel work on companion diagnostics - tests that could predict which patients are most likely to benefit from these drugs.

Genetic biomarkers may help identify patients who are especially responsive to TL1A inhibition. In the tulisokibart ulcerative colitis trial, patients who tested positive for certain genetic markers showed markedly higher response rates: 32% achieved remission compared to 11% on placebo (5). While these specific findings are from a UC study, the principle of genetically-guided treatment selection applies broadly.

This precision medicine approach could be transformative for Crohn's disease care. Rather than the current trial-and-error approach to biologic selection - where patients may cycle through multiple drugs over months or years before finding one that works - genetic testing could help doctors match the right patient to the right drug earlier in their treatment journey. For those of us who have experienced the frustration of waiting to see if a new medication will work, the prospect of more targeted prescribing is genuinely exciting.

What This Means for Patients: Timeline and Next Steps

Understanding where TL1A inhibitors stand in the development process helps set realistic expectations about when these treatments might become available.

When Could TL1A Inhibitors Become Available?

Phase 3 trials are now underway, including Merck's ARES-CD trial for tulisokibart in Crohn's disease (5). Phase 3 studies are the final and largest stage of clinical testing before regulatory submission, and they typically take two to three years to complete.

If Phase 3 results are positive, the earliest possible regulatory approval could come in 2027 or 2028. Approval timelines vary by country - the FDA (United States), EMA (European Union), MHRA (United Kingdom), and other regulatory agencies each have their own review processes and schedules. Access and reimbursement policies also differ significantly from country to country.

It is worth noting that positive Phase 2 results do not guarantee Phase 3 success. Drug development is inherently uncertain, and some promising candidates do not make it through larger trials. That said, the strength and consistency of the TL1A data so far is reason for cautious optimism.

Questions to Ask Your Doctor

If TL1A inhibitors interest you, consider discussing the following with your gastroenterologist:

• Clinical trial participation: Patients can search ClinicalTrials.gov for active TL1A studies that may be accepting enrollment in their area. Participating in a trial offers access to investigational treatments and contributes to the evidence that could help future patients.
• Your current treatment trajectory: If you have stricturing disease or have not responded well to existing biologics, ask your doctor about emerging options and whether you might be a candidate for a clinical trial.
• Genetic testing: As companion diagnostics develop, ask whether genetic biomarker testing relevant to TL1A response is available or forthcoming.

Frequently Asked Questions

What makes TL1A inhibitors different from biologics already used for Crohn's disease?

TL1A inhibitors target a pathway involved in both inflammation and intestinal fibrosis. Current biologics such as anti-TNF drugs and IL-23 inhibitors primarily address inflammation. No approved Crohn's treatment directly targets fibrosis, making TL1A inhibitors potentially the first drug class to tackle both processes simultaneously (3, 4).

Are TL1A inhibitors available yet?

No. TL1A inhibitors for Crohn's disease are still investigational and undergoing clinical trials. Phase 3 trials are currently underway. If results are positive, the earliest possible regulatory approvals could come in 2027 or 2028, with availability varying by country.

What are the side effects of TL1A inhibitors?

In Phase 2 trials, both tulisokibart and duvakitug showed acceptable safety profiles with mostly mild-to-moderate adverse events (1, 2). However, long-term safety data from larger Phase 3 trials is still being collected and will be essential for a complete safety picture.

Can I join a clinical trial for a TL1A inhibitor?

Possibly. Active TL1A clinical trials may be accepting participants. You can search ClinicalTrials.gov for current studies and discuss eligibility with your gastroenterologist, who can help determine whether a trial is appropriate for your specific situation.

Could TL1A inhibitors help patients who already have strictures?

Preclinical research showed that TL1A inhibition reversed collagen deposition in gut tissue (3), suggesting potential to address existing fibrosis. However, this has not yet been confirmed in human clinical trials specifically studying stricturing disease. Larger studies will be needed to answer this question definitively.

Will genetic testing determine if TL1A inhibitors will work for me?

Companion diagnostics are in development. Early data from a tulisokibart trial in ulcerative colitis showed that patients with certain genetic biomarkers had higher response rates (5). Similar approaches may be developed for Crohn's disease, potentially allowing doctors to predict which patients will benefit most.

How do TL1A inhibitors compare to IL-23 inhibitors or anti-TNF drugs?

Direct head-to-head trials comparing TL1A inhibitors with other biologic classes have not been conducted. TL1A inhibitors target a distinct pathway and may offer anti-fibrotic benefits that other biologics do not. Once Phase 3 data is available, clearer comparisons will be possible. In the meantime, your gastroenterologist can help you weigh the existing evidence for each class.

References

1. Teva and Sanofi. Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 Reinforcing Best-in-Class Potential of Duvakitug in Ulcerative Colitis and Crohn's Disease. 2025. Read press release
2. Sands, B.E., et al. Safety and efficacy of the anti-TL1A monoclonal antibody tulisokibart for Crohn's disease: a phase 2a induction trial. 2025. View on PubMed
3. Tam, A., et al. TL1A inhibition for inflammatory bowel disease treatment: From inflammation to fibrosis. 2024. View on PubMed
4. Solitano, V., et al. The TL1A inhibitors in IBD: what's in the pot? 2025. View on PubMed
5. Exploring the Potential of TL1A Inhibition in the Treatment of Inflammatory Bowel Disease Patients. Gastroenterology & Hepatology, 2025. Read article